Research Analysts Set Expectations for Stoke Therapeutics, Inc.’s Q3 2023 Earnings (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Rating) – Analysts at SVB Leerink issued their Q3 2023 earnings estimates for Stoke Therapeutics in a research report issued to clients and investors on Monday, March 6th. SVB Leerink analyst R. Li expects that the company will post earnings per share of ($0.73) for the quarter. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.90) per share. SVB Leerink also issued estimates for Stoke Therapeutics’ FY2023 earnings at ($2.80) EPS, FY2024 earnings at ($3.20) EPS, FY2025 earnings at ($3.00) EPS and FY2026 earnings at ($2.10) EPS.

Stoke Therapeutics (NASDAQ:STOK – Get Rating) last announced its quarterly earnings data on Monday, March 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.06. The business had revenue of $3.27 million for the quarter, compared to analysts’ expectations of $2.93 million. Stoke Therapeutics had a negative net margin of 814.73% and a negative return on equity of 47.38%.

A number of other analysts have also recently weighed in on the stock. Wedbush decreased their target price on shares of Stoke Therapeutics from $33.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 target price on shares of Stoke Therapeutics in a research note on Tuesday. Credit Suisse Group decreased their target price on shares of Stoke Therapeutics from $32.00 to $28.00 and set an “outperform” rating on the stock in a research note on Tuesday. Finally, Bank of America cut shares of Stoke Therapeutics from a “buy” rating to an “underperform” rating and decreased their target price for the stock from $22.00 to $9.00 in a research note on Friday, January 6th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Stoke Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.57.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK opened at $8.85 on Thursday. The company’s 50 day simple moving average is $9.21 and its 200 day simple moving average is $10.94. The stock has a market capitalization of $390.73 million, a price-to-earnings ratio of -3.40 and a beta of 0.42. Stoke Therapeutics has a 1 year low of $6.88 and a 1 year high of $26.60.

Insider Transactions at Stoke Therapeutics

In other news, insider Barry Ticho sold 9,235 shares of Stoke Therapeutics stock in a transaction on Monday, February 6th. The shares were sold at an average price of $10.02, for a total transaction of $92,534.70. Following the transaction, the insider now owns 111,725 shares in the company, valued at $1,119,484.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders have sold 9,702 shares of company stock worth $97,205. Company insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. DekaBank Deutsche Girozentrale lifted its holdings in Stoke Therapeutics by 100.0% in the third quarter. DekaBank Deutsche Girozentrale now owns 20,000 shares of the company’s stock valued at $257,000 after buying an additional 10,000 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Stoke Therapeutics by 43.5% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 17,161 shares of the company’s stock valued at $227,000 after buying an additional 5,204 shares during the period. Bank of Montreal Can acquired a new position in Stoke Therapeutics in the second quarter valued at $13,793,000. Ensign Peak Advisors Inc lifted its holdings in Stoke Therapeutics by 3,397.6% in the second quarter. Ensign Peak Advisors Inc now owns 41,622 shares of the company’s stock valued at $550,000 after buying an additional 40,432 shares during the period. Finally, Los Angeles Capital Management LLC lifted its holdings in Stoke Therapeutics by 22.6% in the second quarter. Los Angeles Capital Management LLC now owns 28,223 shares of the company’s stock valued at $373,000 after buying an additional 5,210 shares during the period.

Stoke Therapeutics Company Profile

(Get Rating)

Stoke Therapeutics, Inc is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.